JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265870

Human TM9SF4 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TM9SF4 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

KIAA0255, TM9S4_HUMAN, Transmembrane 9 superfamily member 4, Transmembrane 9 superfamily protein member 4

1 Images
Sanger Sequencing - Human TM9SF4 knockout HeLa cell line (AB265870)
  • Sanger seq

Unknown

Sanger Sequencing - Human TM9SF4 knockout HeLa cell line (AB265870)

Homozygous : 1 bp insertion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265870-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265870 Human TM9SF4 knockout HeLa cell line", "number":"AB265870-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265870-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265870-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265870-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265870 Human TM9SF4 knockout HeLa cell line", "number":"AB265870-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265870-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265870 Human TM9SF4 knockout HeLa cell line", "number":"AB265870-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265870-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265870 Human TM9SF4 knockout HeLa cell line", "number":"AB265870-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TM9SF4
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TM9SF4 also known as Transmembrane 9 Superfamily Member 4 is a multi-pass membrane protein with an approximate molecular mass of 70 kDa. It is localized in the Golgi apparatus and endosomes showing a notable expression in immune-related cells such as macrophages and dendritic cells. TM9SF4 is involved in the transport and sorting of proteins within cellular compartments playing an important role in maintaining intracellular pH homeostasis by modulating ion exchange across membranes.
Biological function summary

As part of a larger protein family TM9SF4 is involved in the regulation of cellular processes like endocytosis and exocytosis. It functions as a regulator of phagocytosis a process critical for immune response and cell clearance. Through its action in cellular compartments it contributes to antigen presentation thereby influencing cellular immune responses. Its involvement in these pathways highlights its significance in both normal cellular functions and immune system regulation.

Pathways

TM9SF4 influences processes associated with the endocytic pathway and vesicular trafficking. It interacts within cellular networks involving SNARE proteins responsible for vesicle fusion highlighting its role in transport pathways. TM9SF4 also associates with V-ATPase complexes affecting acidic environments necessary for hydrolytic enzymes in endosomes. Through these connections TM9SF4 helps sustain cellular dynamics and integrity.

TM9SF4 links to immune-related conditions particularly chronic inflammatory diseases. It affects macrophage function and inflammation making it relevant in disorders such as rheumatoid arthritis. Additionally TM9SF4 alterations associate with tumor microenvironments influencing cancer progression. Through its modulation of phagocytic functions abnormalities in TM9SF4 activity can alter interactions with proteins like TNF-alpha which are important in inflammation and cancer-related pathways.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com